Centogene (CNTG): Bathi resik saben saham (EPS TTM)

A high proportion of fixed costs for genetic testing constrains the operating leverage of Centogene N.V. (CNTG), as illustrated by the TTM earnings per share chart, where the indicator reaches -1.39. Growth potential is driven by an elite staff of bioinformaticians and a unique AI platform for rare diseases, transforming the company into a key B2B hub for global developers of orphan drugs.

This indicator is calculated by dividing the total annual net profit by the total number of shares. The metric determines the real return per share, excluding quarterly reporting fluctuations. For Centogene N.V. (CNTG), this figure reflects the efficiency of monetizing unique biodata and the pricing power applied to diagnostics. By analyzing the rolling net profit per share, an investor assesses the balance between current income and development costs.